AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.

Merck & Co. struck a deal with Brazil's Butantan Institute to push ahead with their respective dengue development programs.

BMS’s Opdivo failed a key small cell lung cancer trial in October, but the results may still be enough to protect the approval it already has.

India’s stock regulators say they're examining a whistleblower complaint against top domestic drugmaker Sun Pharma.

Last May, Neurocrine’s Ingrezza failed a Tourette syndrome trial, prompting the company to design a new one. But the drug has failed that trial, too.

After Merck abandoned its Lantus biosimilar, Mylan is still pressing forward and won a patent challenge against Sanofi.

With about $225 million in hand from the IPO, Orchard Therapeutics is starting on a plant in California for its gene therapy candidates.

Alnylam and Ionis have until just after the start of the new year to appeal NICE's conclusion that their new ATTR drugs are not cost-effective.

Johnson & Johnson’s Tremfya may have debuted behind Novartis' Cosentyx, but it has now topped the blockbuster in a head-to-head trial.